Division of Imaging Sciences, School of Medicine, King's College London, London, United Kingdom.
Invest Radiol. 2012 Jan;47(1):2-4. doi: 10.1097/RLI.0b013e318229ff3e.
With the emergence of novel targeted therapies, imaging techniques that assess tumor vascular support have gained credence for response assessment alongside standard response criteria. Computed tomography (CT) perfusion techniques that quantify regional tumor blood flow, blood volume, flow-extraction product, and permeability-surface area product through standard kinetic models are attractive, but the level of evidence for CT perfusion to be a truly mature biomarker remains insufficient. Studies to date have not been powered to assess this. Future studies that include good quality prospective validation correlating perfusion CT to outcome end points in the trial setting are needed to take CT perfusion forward as a biomarker in oncology.
随着新型靶向治疗的出现，评估肿瘤血管支持的成像技术已经获得了认可，可以与标准的反应标准一起评估反应。通过标准动力学模型定量区域肿瘤血流、血容量、流量提取产物和通透性表面积产物的计算机断层扫描（CT）灌注技术很有吸引力，但 CT 灌注成为真正成熟的生物标志物的证据水平仍然不足。迄今为止，还没有研究有足够的能力来评估这一点。需要进行前瞻性的高质量研究，将灌注 CT 与试验中的结果终点相关联，以将 CT 灌注作为肿瘤学中的生物标志物向前推进。
